Palisade Bio (NASDAQ:PALI) Now Covered by Analysts at HC Wainwright

HC Wainwright initiated coverage on shares of Palisade Bio (NASDAQ:PALI) in a report released on Thursday morning, Marketbeat reports. The brokerage issued a buy rating and a $7.00 target price on the stock.

PALI has been the topic of a number of other reports. Clear Str raised Palisade Bio to a “strong-buy” rating in a research report on Monday, December 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of Palisade Bio in a research report on Thursday, January 22nd. Piper Sandler assumed coverage on Palisade Bio in a research note on Monday, December 29th. They set an “overweight” rating and a $25.00 target price on the stock. Stifel Nicolaus assumed coverage on Palisade Bio in a research report on Wednesday, February 25th. They set a “buy” rating and a $5.00 target price on the stock. Finally, Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $11.00.

Palisade Bio Stock Down 2.0%

NASDAQ:PALI opened at $1.96 on Thursday. Palisade Bio has a 52 week low of $0.53 and a 52 week high of $2.64. The firm has a 50 day moving average of $1.78 and a 200 day moving average of $1.73. The stock has a market capitalization of $325.12 million, a price-to-earnings ratio of -0.92 and a beta of 1.53.

Institutional Investors Weigh In On Palisade Bio

Institutional investors and hedge funds have recently modified their holdings of the company. Cetera Investment Advisers purchased a new stake in Palisade Bio in the fourth quarter valued at approximately $25,000. Schonfeld Strategic Advisors LLC purchased a new position in Palisade Bio during the 4th quarter worth approximately $26,000. Virtu Financial LLC acquired a new stake in Palisade Bio during the 4th quarter valued at approximately $28,000. Atom Investors LP acquired a new stake in Palisade Bio during the 4th quarter valued at approximately $33,000. Finally, Barclays PLC purchased a new stake in shares of Palisade Bio in the 4th quarter valued at $35,000. Institutional investors and hedge funds own 11.79% of the company’s stock.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.